Sam Brusco, Associate Editor02.08.24
Delve Health, a company focused on digital healthcare and decentralized clinical trial biotech, has begun a collaboration with AliveCor.
The duo will integrate AliveCor’s KardiaMobile 6L personal electrocardiogram (ECG) with Delve’s LiveCare Link + smart RPM (remote patient monitoring) gateway. They hope the partnership will foster new research initiatives, accelerate drug development processes, and open possibilities for innovative treatments.
KardiaMobile 6L lets clinicians monitor heart rhythm and spot abnormalities like atrial fibrillation (AFib) in real-time. The device can then transmit data to healthcare providers, who can view it through Delve Health’s Clinical StudyPal platform. This can offer timely feedback in clinical trials as well as quick interventions.
The pair also said the combined technologies will allow passive collection of real-world data and real-world evidence. The collaboration hopes to reduce site and patient burdens during clinical trials, allowing sponsors to make more informed decisions, more quickly, based on real-time data collected.
"We are thrilled to partner with AliveCor in this exciting endeavor," said Delve Health founder and CEO Wessam Sonbol. "This collaboration aligns perfectly with our mission of transforming healthcare through data-driven insights. By combining our fully customizable, end-to-end platform with AliveCor's KardiaMobile, a cardiology-specific medical device, we can make significant strides in improving patient care and positively impacting global health outcomes."
"Delve Health's capabilities in data analytics will significantly and safely accelerate the clinical trial timeline,” added Delve Health’s VP of global biopharma partnerships. "Together, we have the opportunity to revolutionize how healthcare solutions are developed and deployed, ultimately benefiting patients and healthcare providers worldwide."
In August 2023, AliveCor began partnerships with Clario to bring ECG tech home for clinical trials as well as with Luscii for cardiac care treatment.
The duo will integrate AliveCor’s KardiaMobile 6L personal electrocardiogram (ECG) with Delve’s LiveCare Link + smart RPM (remote patient monitoring) gateway. They hope the partnership will foster new research initiatives, accelerate drug development processes, and open possibilities for innovative treatments.
KardiaMobile 6L lets clinicians monitor heart rhythm and spot abnormalities like atrial fibrillation (AFib) in real-time. The device can then transmit data to healthcare providers, who can view it through Delve Health’s Clinical StudyPal platform. This can offer timely feedback in clinical trials as well as quick interventions.
The pair also said the combined technologies will allow passive collection of real-world data and real-world evidence. The collaboration hopes to reduce site and patient burdens during clinical trials, allowing sponsors to make more informed decisions, more quickly, based on real-time data collected.
"We are thrilled to partner with AliveCor in this exciting endeavor," said Delve Health founder and CEO Wessam Sonbol. "This collaboration aligns perfectly with our mission of transforming healthcare through data-driven insights. By combining our fully customizable, end-to-end platform with AliveCor's KardiaMobile, a cardiology-specific medical device, we can make significant strides in improving patient care and positively impacting global health outcomes."
"Delve Health's capabilities in data analytics will significantly and safely accelerate the clinical trial timeline,” added Delve Health’s VP of global biopharma partnerships. "Together, we have the opportunity to revolutionize how healthcare solutions are developed and deployed, ultimately benefiting patients and healthcare providers worldwide."
In August 2023, AliveCor began partnerships with Clario to bring ECG tech home for clinical trials as well as with Luscii for cardiac care treatment.